Literature DB >> 15375496

Antioxidative response for nitric oxide production in breast carcinoma.

Peeter Karihtala1, Vuokko L Kinnula, Ylermi Soini.   

Abstract

Our aim was to study the role of oxidant and nitric oxide (NO)-derived damage in human breast carcinomas by studying the expression of nitrotyrosine in tumor tissue. To elucidate whether nitrotyrosine levels associate with NO synthesis and have an effect on antioxidative enzyme response or angiogenesis, we also studied the expression of all three nitric oxide synthases (NOS), manganese superoxide dismutase (MnSOD), catalase and vascular endothelial growth factor (VEGF) in the tumors. A large set of breast cancer samples in microarray blocks were stained with antibodies to nitrotyrosine, iNOS, eNOS, nNOS, MnSOD, catalase and VEGF. Nitrotyrosine expression was seen in 56% of the cases. There was a close relationship between the expression of nitrotyrosine and all three NOS isoforms (for all p<0.0005), catalase (p<0.0005) and MnSOD (p=0.043), in addition enlarged tumor size was in association with high nitrotyrosine (p=0.046), eNOS (p=0.005) and VEGF (p=0.046) levels. Our findings suggest that NO-derived oxidative damage takes place and its level associates to NOS synthesis in human breast cancer. The current results also imply the attempt of cells to hedge against effects of NO by increasing their MnSOD and catalase expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375496

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.

Authors:  Ubaldo E Martinez-Outschoorn; Renee M Balliet; Dayana B Rivadeneira; Barbara Chiavarina; Stephanos Pavlides; Chenguang Wang; Diana Whitaker-Menezes; Kristin M Daumer; Zhao Lin; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Erik S Knudsen; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

Review 2.  NO to breast: when, why and why not?

Authors:  Shehla Pervin; Gautam Chaudhuri; Rajan Singh
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  Oxidatively modified proteins as plasma biomarkers in breast cancer.

Authors:  Hongjun Jin; Don S Daly; Jeffrey R Marks; Richard C Zangar
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

4.  Protein modifications as potential biomarkers in breast cancer.

Authors:  Hongjun Jin; Richard C Zangar
Journal:  Biomark Insights       Date:  2009-11-30

5.  Active nNOS Is Required for Grp94-Induced Antioxidant Cytoprotection: A Lesson from Myogenic to Cancer Cells.

Authors:  Filippo Fornasiero; Cristina Scapin; Maurizio Vitadello; Paola Pizzo; Luisa Gorza
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.